Dr. Dale Randall Shepard, MD, PhD

Dr. Shepard practices at Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation.

Dr. Shepard's NPI, 1790955623, was assigned on March 6, 2008. Dr. Shepard graduated from Ohio State University College of Medicine in 2003. Dr. Shepard holds Ohio license 35.093461.

Dr. Shepard's primary practice is Cleveland Clinic Main Campus, at 9500 Euclid Avenue, Cleveland, OH 44195 in Cuyahoga County. The practice phone is (216) 952-9829.

Dr. Shepard's primary practice is Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation. Dr. Shepard is also affiliated with Fairview Hospital. The medical group on file is Cleveland Clinic. Dmand AI also links Dr. Shepard to 1 more hospital and 2 clinical labs, each named with a free account. Dr. Shepard's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shepard practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shepard's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Shepard is licensed in Ohio.

CMS data shows 227 Medicare services from Dr. Shepard across 5 procedure codes in 2024, for 112 Medicare patients. Medicare paid $14,325 for them.

CMS counts 112 Medicare patients who saw Dr. Shepard in 2024. The largest group is 65 to 74, with 58 patients. 65% of them have high blood pressure, and 60% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shepard's median patient age at 60, with 56% women.

In 2024, Dr. Shepard wrote 284 Medicare Part D claims for 57 patients. 67% of them were for generic drugs. CMS names the drug for 141 of them, across 6 drugs with 11 or more claims each, at $1,866,602 in total drug cost. In 2023, CMS named 117 claims across 5 drugs.

Dr. Shepard accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shepard as offering telehealth.

Dmand AI links 35 papers to Dr. Shepard, published from 2010 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Antineoplastic Agents, Antibodies, Monoclonal, Humanized and Antineoplastic Combined Chemotherapy Protocols. Dr. Shepard has published most often in Cancer Chemother Pharmacol. Dr. Shepard's most frequent co-authors are Nathan Wesley Mesko, MD, Lukas M. Nystrom, MD and Gannon Lee Curtis, MD.

Dmand AI links Dr. Shepard to 10 clinical trials, 6 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Ovarian Epithelial, Cystadenocarcinoma, Mucinous and Hemangioendothelioma. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 665 general payments to Dr. Shepard from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Sanofi and Genzyme US Companies paid the most, $294,962. It also lists 7 research payments totaling $1,262 from 2019 to 2024.

Dr. Shepard graduated from Ohio State University College of Medicine in 2003.